# CXCR4 Chemokine Receptor: T-Tropic HIV Entry, CXCL12 Signaling Axis, and Small-Molecule Antagonists ## Key Takeaways - CXCR4 is a seven-transmembrane G protein-coupled receptor that serves as the exclusive receptor for CXCL12 and a critical co-receptor for T-tropic (X4) strains of HIV-1, mediating viral entry via interaction with the gp120 envelope glycoprotein. - Gain-of-function mutations in *CXCR4*, particularly truncating mutations in the C-terminus, cause WHIM syndrome, characterized by impaired receptor desensitization and internalization, leading to myelokathexis and recurrent infections. - Somatic *CXCR4* mutations, such as C1013G and S338X, are prevalent in Waldenström macroglobulinemia and contribute to ibrutinib resistance and aggressive disease, while promoter mutations in colorectal cancer are linked to metastasis. - Plerixafor (AMD3100) is an FDA-approved small-molecule CXCR4 antagonist used to mobilize hematopoietic stem cells, and numerous other small-molecule antagonists and monoclonal antibodies are under investigation for HIV/AIDS and various cancers. - CXCR4 signaling is complex, involving canonical Gαi/o pathways, β-arrestin-mediated desensitization and internalization, and non-canonical pathways like JAK/STAT and Wnt/β-catenin, all tightly regulated by feedback mechanisms. - Post-translational modifications, including N-linked glycosylation, tyrosine sulfation at Tyr21/Tyr27 (essential for CXCL12 and gp120 binding), and palmitoylation, are crucial for CXCR4's cell surface expression, ligand affinity, and signaling capacity. --- ## Executive Summary & Key Metadata CXCR4 (C-X-C chemokine receptor type 4) is a seven-transmembrane G protein-coupled receptor (GPCR) that serves as the exclusive receptor for the chemokine CXCL12 (stromal cell-derived factor-1, SDF-1). Beyond its physiological roles in hematopoiesis, immune cell trafficking, and embryonic development, CXCR4 is a co-receptor for T-tropic (X4) strains of human immunodeficiency virus type 1 (HIV-1). The receptor is a high-priority therapeutic target in oncology (metastasis, tumor microenvironment) and in HIV/AIDS management. The following table summarizes the core metadata for this gene. | Attribute | Value | |---|---| | HGNC Symbol | CXCR4 | | UniProt Accession | P61073 | | Representative PDB ID | 3ODU (human CXCR4 with antagonist IT1t) | | Chromosomal Locus | 2q22.1 | | Primary Molecular Function | C-X-C chemokine receptor activity; G protein-coupled receptor signaling; CXCL12 binding; HIV-1 co-receptor activity | | Disease & Pathology Associations | WHIM syndrome (warts, hypogammaglobulinemia, infections, myelokathexis); HIV-1 susceptibility; various cancers (metastasis, proliferation); colorectal cancer; breast cancer; leukemia | | Primary Ligand | CXCL12 (SDF-1α) | | Canonical G Protein | Gαi/o | | FDA-Approved Antagonist | Plerixafor (AMD3100, Mozobil) | ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The *CXCR4* gene is located on the long arm of human chromosome 2 at cytogenetic band 2q22.1. The gene spans approximately 8.2 kilobases (kb) of genomic DNA (GRCh38/hg38: chr2:136,114,349-136,118,149, minus strand). The locus is gene-dense, with the *CXCR4* gene positioned in a head-to-tail orientation relative to neighboring genes, including *FZD7* (frizzled class receptor 7) and *THSD7B* (thrombospondin type 1 domain containing 7B). The genomic region is characterized by a high density of Alu repetitive elements, which have been implicated in recombination events leading to copy number variations in some populations. The coding sequence of *CXCR4* is organized into two exons separated by a single large intron of approximately 5.4 kb. Exon 1 (approximately 100 bp) contains the 5' untranslated region (5' UTR) and the start codon (ATG) encoding the initiator methionine. Exon 2 (approximately 1.1 kb) encodes the remainder of the open reading frame (ORF) and the complete 3' UTR. The full-length transcript (NM_003467.3) is 1,839 nucleotides in length, encoding a 352-amino acid protein. ### 1.2 Promoter Architecture and Transcriptional Regulation The *CXCR4* promoter is a TATA-less, GC-rich region located immediately upstream of exon 1. It contains multiple Sp1 (specificity protein 1) binding sites, which are critical for basal transcriptional activity. The core promoter spans approximately 200 bp upstream of the transcription start site (TSS) and includes several cis-acting elements: - **Sp1 sites**: Three consensus GC-box motifs (GGGCGG) at positions -50, -80, and -120 relative to the TSS. Sp1 binding is essential for constitutive expression in most cell types. - **NF-κB site**: A consensus κB element (GGGACTTTCC) at position -60. This site mediates inducible expression in response to inflammatory cytokines (TNF-α, IL-1β) and in activated T cells. - **Hypoxia response element (HRE)**: A binding site for hypoxia-inducible factor 1α (HIF-1α) at position -30. Under hypoxic conditions, HIF-1α translocates to the nucleus and upregulates CXCR4 transcription, a mechanism that contributes to tumor cell invasion in hypoxic microenvironments. - **E-box elements**: Two canonical E-box motifs (CANNTG) at positions -140 and -170, which are recognized by basic helix-loop-helix (bHLH) transcription factors such as c-Myc and upstream stimulatory factors (USF1/USF2). c-Myc directly transactivates CXCR4, linking oncogenic Myc signaling to enhanced chemotactic responsiveness. ### 1.3 Enhancer Elements and Chromatin Architecture Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveal several enhancer-associated histone marks (H3K27ac, H3K4me1) within intron 1 and approximately 5 kb upstream of the TSS. A distal enhancer element at chr2:136,110,500-136,112,000 (approximately 4 kb upstream) has been shown to interact with the promoter via chromatin looping in CD4+ T lymphocytes. This enhancer contains binding sites for STAT5 (signal transducer and activator of transcription 5) and RUNX1 (runt-related transcription factor 1), both of which are critical for hematopoietic lineage-specific expression. Single-nucleotide polymorphisms (SNPs) within this enhancer region (e.g., rs17844048) have been associated with altered CXCR4 surface expression levels and differential susceptibility to HIV-1 infection in some cohorts. ### 1.4 Alternative Splicing and Isoforms Alternative splicing of the *CXCR4* primary transcript generates multiple mRNA isoforms, although the functional significance of most remains incompletely characterized: - **CXCR4-001 (canonical)**: Encodes the full-length 352-amino acid receptor. This is the predominant isoform expressed on the cell surface. - **CXCR4-002 (variant 2)**: Retains a portion of intron 1, introducing a premature stop codon. This isoform is predicted to encode a truncated 38-amino acid peptide that is likely subject to nonsense-mediated decay (NMD). Its expression has been detected in some cancer cell lines, but no functional protein product has been confirmed. - **CXCR4-003 (variant 3)**: Uses an alternative splice acceptor site in exon 2, resulting in an in-frame deletion of 12 amino acids (residues 233-244) within the third intracellular loop (ICL3). This deletion disrupts G protein coupling and results in a receptor that is expressed on the cell surface but is signaling-incompetent. Co-expression of this variant with the canonical receptor exerts a dominant-negative effect, reducing CXCL12-mediated chemotaxis. - **CXCR4-004 (variant 4)**: A recently described isoform that skips exon 1 and uses a cryptic TSS within intron 1. This transcript produces a protein with an altered N-terminus (lacking the first 22 amino acids). The truncated N-terminus reduces CXCL12 binding affinity but preserves HIV-1 co-receptor function, suggesting differential ligand-receptor requirements for these two interactions. ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Topology and Domain Boundaries CXCR4 is a class A (rhodopsin-like) GPCR with a canonical seven-transmembrane (7TM) architecture. The protein is oriented with an extracellular N-terminus, three extracellular loops (ECL1-3), three intracellular loops (ICL1-3), and an intracellular C-terminus. The domain boundaries, based on the crystal structure of CXCR4 bound to the small-molecule antagonist IT1t (PDB: 3ODU), are as follows: | Domain | Residue Range | Structural/Functional Role | |---|---|---| | N-terminus (NT) | 1-38 | Ligand binding (CXCL12); HIV-1 gp120 binding; sulfotyrosine modifications at Tyr21 and Tyr27 | | Transmembrane helix 1 (TM1) | 39-63 | Structural scaffold; participates in receptor activation | | Intracellular loop 1 (ICL1) | 64-74 | G protein coupling (minor) | | Transmembrane helix 2 (TM2) | 75-99 | Ligand binding pocket; forms disulfide bond with ECL2 | | Extracellular loop 1 (ECL1) | 100-108 | Contributes to ligand entry | | Transmembrane helix 3 (TM3) | 109-133 | Contains DRY motif (Asp133-Arg134-Tyr135); critical for G protein activation | | Intracellular loop 2 (ICL2) | 134-145 | G protein coupling (major); interacts with Gαi | | Transmembrane helix 4 (TM4) | 146-170 | Structural stability; dimerization interface | | Extracellular loop 2 (ECL2) | 171-197 | Forms a β-hairpin; contains Cys186 (disulfide bond to Cys109 in TM3); major ligand binding determinant | | Transmembrane helix 5 (TM5) | 198-222 | Ligand binding; conformational changes during activation | | Intracellular loop 3 (ICL3) | 223-232 | G protein coupling; β-arrestin recruitment | | Transmembrane helix 6 (TM6) | 233-257 | Contains CWxP motif; undergoes outward movement upon activation | | Extracellular loop 3 (ECL3) | 258-262 | Minor contribution to ligand binding | | Transmembrane helix 7 (TM7) | 263-286 | Contains NPxxY motif (Asn283-Pro284-x-x-Tyr287); critical for receptor activation | | Helix 8 (H8) | 287-300 | Intracellular amphipathic helix; palmitoylation sites (Cys288, Cys289) | | C-terminus (CT) | 301-352 | Phosphorylation sites (Ser/Thr); β-arrestin binding; internalization motifs | ### 2.2 Ligand Binding Pocket The orthosteric binding pocket of CXCR4 is a large, solvent-exposed cavity formed by the transmembrane helices (TM1-TM7) and the extracellular loops. Unlike many class A GPCRs, the CXCR4 pocket extends toward the extracellular surface, allowing both small molecules and the large chemokine ligand CXCL12 to access the binding site. Key residues involved in antagonist binding (as determined by the 3ODU structure with IT1t) include: - **TM1**: Asp97 (forms a salt bridge with the protonated amine of IT1t) - **TM2**: Asp187 (in ECL2; coordinates the isothiourea moiety) - **TM3**: Tyr116, Tyr135 (aromatic stacking interactions) - **TM5**: His203, His281 (coordinate the imidazothiazole ring) - **TM6**: Trp252, Glu288 (hydrogen bonding network) - **TM7**: Asp262 (critical for CXCL12 binding; mutation D262A abolishes ligand-induced signaling) The binding of CXCL12 involves a two-step mechanism: (1) the chemokine's N-terminal region (residues 1-8, KPVSLSYR) binds to the receptor's N-terminus and ECL2, and (2) the chemokine's core domain (the 40s loop and 50s loop) interacts with the transmembrane pocket. The N-terminus of CXCR4 undergoes post-translational sulfation at Tyr21 and Tyr27, which creates a negatively charged surface that electrostatically complements the positively charged residues (Arg8, Lys24, Arg41) of CXCL12. ### 2.3 Post-Translational Modifications CXCR4 is subject to extensive post-translational modifications that regulate its function, trafficking, and signaling: - **N-linked glycosylation**: Asn11 and Asn22 in the N-terminus are modified with complex-type glycans. Glycosylation is required for efficient cell surface expression; treatment with tunicamycin (an N-glycosylation inhibitor) reduces surface CXCR4 levels by 70%. - **Tyrosine sulfation**: Tyr21 and Tyr27 are sulfated by tyrosylprotein sulfotransferases (TPST1/TPST2). Sulfation enhances CXCL12 binding affinity by approximately 10-fold and is essential for HIV-1 gp120 recognition. - **Palmitoylation**: Cys288 and Cys289 in helix 8 are palmitoylated, anchoring the C-terminus to the plasma membrane. This modification is required for proper G protein coupling and receptor signaling. - **Phosphorylation**: Following agonist stimulation, multiple Ser/Thr residues in the C-terminus (Ser324, Ser325, Ser330, Ser339, Ser346, Ser347, Thr348) are phosphorylated by G protein-coupled receptor kinases (GRKs). Phosphorylation creates binding sites for β-arrestins, leading to receptor desensitization and internalization. ### 2.4 Oligomerization and Structural Dynamics CXCR4 forms both homodimers and heterodimers. The crystal structure (3ODU) reveals a homodimer interface involving TM3, TM4, and TM5, with a buried surface area of approximately 1,100 Ų. Dimerization is constitutive and occurs in the endoplasmic reticulum before cell surface expression. Heterodimerization with other chemokine receptors, particularly CCR2 and CCR5, has been demonstrated using bioluminescence resonance energy transfer (BRET). Heterodimerization with CCR5 alters ligand selectivity and signaling properties, and may influence HIV-1 co-receptor usage. ### 2.5 Interactive 3D Visualizer [Interactive 3D Protein Visualizer: Load CXCR4 (PDB: 3ODU)](/tools/protein-structure-viewer?source=direct&pdbId=3ODU) The interactive viewer allows rotation, zoom, and residue-level inspection of the CXCR4 structure. Key features to explore include: (1) the orthosteric binding pocket with IT1t, (2) the disulfide bond between Cys109 (TM3) and Cys186 (ECL2), (3) the DRY motif at the cytoplasmic face of TM3, and (4) the palmitoylation sites at the C-terminus. ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Canonical Gαi Signaling CXCR4 is a Gαi/o-coupled receptor. Upon CXCL12 binding, the receptor undergoes a conformational change that promotes the exchange of GDP for GTP on the Gαi subunit, leading to dissociation of the Gαi-GTP and Gβγ subunits. The primary downstream effectors are: - **Inhibition of adenylyl cyclase**: Gαi directly inhibits adenylyl cyclase, reducing intracellular cAMP levels. This leads to decreased protein kinase A (PKA) activity, which modulates gene expression and ion channel activity. - **Activation of PI3K/AKT pathway**: The Gβγ subunit activates phosphoinositide 3-kinase γ (PI3Kγ), which generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3) at the plasma membrane. PIP3 recruits AKT (protein kinase B) to the membrane, where it is phosphorylated and activated by PDK1 and mTORC2. AKT promotes cell survival, proliferation, and migration. - **Activation of PLCβ**: Gβγ activates phospholipase Cβ (PLCβ), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). Calcium mobilization is a hallmark of CXCR4 activation and is required for chemotaxis. - **Ras/MAPK pathway**: Gβγ activates the Ras-Raf-MEK-ERK cascade through the adaptor protein Shc and the guanine nucleotide exchange factor SOS. ERK1/2 translocates to the nucleus and phosphorylates transcription factors such as Elk-1, promoting cell cycle progression. ### 3.2 β-Arrestin-Mediated Signaling Following GRK-mediated phosphorylation, β-arrestin1 and β-arrestin2 bind to the C-terminus of CXCR4. This interaction serves two functions: (1) it sterically hinders further G protein coupling (desensitization), and (2) it initiates clathrin-mediated endocytosis. β-arrestins also act as scaffolds for mitogen-activated protein kinases (MAPKs), particularly JNK3 and ERK1/2, leading to a second wave of signaling that is spatially and temporally distinct from G protein-dependent signaling. β-arrestin-biased signaling through CXCR4 has been implicated in the regulation of cell migration and survival in cancer cells. ### 3.3 Non-Canonical Signaling Pathways - **JAK/STAT pathway**: CXCR4 constitutively associates with JAK2 and JAK3. Upon CXCL12 binding, JAK kinases phosphorylate the receptor on tyrosine residues (Tyr135 in the DRY motif), creating docking sites for STAT transcription factors. Phosphorylated STATs dimerize and translocate to the nucleus, where they regulate genes involved in cell survival and proliferation. - **Wnt/β-catenin pathway**: CXCR4 activation can transactivate the Wnt pathway through the phosphorylation of LRP6 (low-density lipoprotein receptor-related protein 6) and the subsequent stabilization of β-catenin. This cross-talk is particularly relevant in cancer stem cells. - **NF-κB pathway**: CXCL12 stimulation activates the IKK complex, leading to the phosphorylation and degradation of IκBα and the nuclear translocation of NF-κB. This pathway contributes to the expression of pro-inflammatory cytokines and anti-apoptotic genes. ### 3.4 Regulatory Feedback Loops CXCR4 signaling is tightly regulated by multiple feedback mechanisms: - **Homologous desensitization**: Agonist-induced phosphorylation by GRKs and β-arrestin binding leads to rapid (within minutes) loss of signaling capacity. - **Receptor internalization and recycling**: CXCR4 is internalized via clathrin-coated pits and sorted to early endosomes. In most cell types, the receptor is dephosphorylated and recycled back to the plasma membrane (t½ ≈ 30-60 min). However, in some contexts (e.g., WHIM syndrome mutants), the receptor is targeted for lysosomal degradation. - **Transcriptional downregulation**: Prolonged CXCL12 exposure leads to decreased *CXCR4* mRNA levels through the activation of the ubiquitin-proteasome system and the downregulation of Sp1 transcription factor activity. - **Ligand degradation**: CXCL12 is cleaved by matrix metalloproteinases (MMP-2, MMP-9) and dipeptidyl peptidase-4 (DPP4/CD26), generating truncated forms that act as receptor antagonists. ### 3.5 Protein-Protein Interaction Networks CXCR4 interacts with a wide array of proteins beyond its canonical G protein partners. Key interactions (from BioGRID and STRING databases) include: - **CD4**: The T-cell co-receptor for HIV-1; CXCR4 and CD4 form a ternary complex with gp120 during viral entry. - **CXCL12**: The endogenous ligand. - **Gαi1, Gαi2, Gαi3, Gαo**: Heterotrimeric G protein α subunits. - **β-arrestin1/2**: Regulators of desensitization and internalization. - **JAK2, JAK3**: Tyrosine kinases involved in STAT signaling. - **GRK2, GRK3, GRK6**: G protein-coupled receptor kinases. - **HIF-1α**: Transcription factor that regulates CXCR4 expression. - **NOD1**: Nucleotide-binding oligomerization domain-containing protein 1; interacts with CXCR4 to modulate NF-κB signaling. - **CXCR7 (ACKR3)**: Atypical chemokine receptor that forms heterodimers with CXCR4, scavenging CXCL12 and modulating CXCR4 signaling. ```mermaid sequenceDiagram participant L as "CXCL12" participant R as "CXCR4" participant G as "Gαi/Gβγ" participant E as "Effectors (AC, PLCβ, PI3K)" participant B as "β-arrestin" participant C as "Clathrin-coated pit" L->>R: Ligand binding R->>G: GDP→GTP exchange G->>E: Gαi (inhibits AC), Gβγ (activates PLCβ, PI3K) E->>E: ↓cAMP, ↑IP3/DAG, ↑PIP3 E-->>R: Feedback (PKC phosphorylates R) R->>B: GRK phosphorylation → β-arrestin binding B->>C: Clathrin-mediated endocytosis C->>C: Internalization (recycling or degradation) ``` ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 WHIM Syndrome WHIM syndrome (OMIM #193670) is a rare primary immunodeficiency disorder caused by autosomal dominant, gain-of-function mutations in *CXCR4*. The syndrome is characterized by warts (due to human papillomavirus infection), hypogammaglobulinemia, recurrent bacterial infections, and myelokathexis (retention of mature neutrophils in the bone marrow). The underlying mechanism is impaired receptor desensitization and internalization, leading to enhanced and sustained CXCL12-mediated signaling. The vast majority of WHIM-associated mutations are truncating mutations in the C-terminal tail of CXCR4, which delete the phosphorylation sites and β-arrestin binding motifs. Recurrent mutations include: | Mutation | Type | Location | Mechanism | Clinical Phenotype | |---|---|---|---|---| | Arg334Ter (R334X) | Nonsense | C-terminus | Loss of 18 C-terminal residues; impaired β-arrestin binding | Classic WHIM; severe neutropenia | | Ser338Ter (S338X) | Nonsense | C-terminus | Loss of 14 residues; impaired internalization | Classic WHIM | | Glu343Ter (E343X) | Nonsense | C-terminus | Loss of 9 residues; partial internalization defect | Mild WHIM | | 1000_1013del (frameshift) | Frameshift | C-terminus | Altered C-terminal sequence; loss of phosphorylation sites | WHIM with variable penetrance | | Asp84Asn (D84N) | Missense | TM2 | Constitutive signaling; impaired desensitization | Atypical WHIM; severe warts | The R334X mutation is the most common, accounting for approximately 40% of WHIM cases. Functional studies show that R334X CXCR4 exhibits normal ligand binding but fails to undergo agonist-induced internalization, resulting in prolonged cell surface expression and sustained calcium signaling. This leads to aberrant retention of neutrophils in the bone marrow (myelokathexis) and impaired B-cell maturation (hypogammaglobulinemia). ### 4.2 Somatic Mutations in Cancer Somatic *CXCR4* mutations have been identified in several malignancies: - **Waldenström macroglobulinemia (WM)**: The MYD88 L265P mutation is the most common driver, but approximately 30-40% of WM cases also harbor somatic *CXCR4* mutations, most frequently C1013G (leading to a frameshift at Ser338) and S338X. These mutations confer resistance to ibrutinib (a BTK inhibitor) and are associated with more aggressive disease, higher bone marrow involvement, and increased serum IgM levels. - **Diffuse large B-cell lymphoma (DLBCL)**: Recurrent *CXCR4* mutations (e.g., R334X) have been found in the activated B-cell (ABC) subtype, where they promote NF-κB signaling and cell survival. - **Colorectal cancer**: Gain-of-function mutations in the *CXCR4* promoter region (e.g., -11G>A) increase transcriptional activity and are associated with lymph node metastasis and poor prognosis. - **Breast cancer**: Somatic mutations in the *CXCR4* coding region are rare, but overexpression of wild-type CXCR4 is common and correlates with metastasis to lung, liver, and bone. ### 4.3 Germline Polymorphisms Several common SNPs in *CXCR4* have been studied for their association with disease: - **rs2228014 (Ile138Val)**: Located in ICL2. This variant is associated with altered HIV-1 susceptibility in some cohorts, although results are conflicting. In vitro studies show reduced CXCL12-induced chemotaxis for the Val138 allele. - **rs17844048 (C>T)**: Located in the distal enhancer region. The T allele is associated with reduced CXCR4 expression on CD4+ T cells and lower HIV-1 infection rates. - **rs7121 (C>T)**: A synonymous SNP in exon 2 (codon 239). This variant has been associated with altered mRNA stability and differential expression in some tissues. ### 4.4 Clinical Differentials and Diagnostic Considerations The clinical presentation of WHIM syndrome overlaps with other immunodeficiencies, including: - **Severe congenital neutropenia (SCN)**: Caused by mutations in *ELANE*, *HAX1*, or *GFI1*. Unlike WHIM, SCN typically presents with severe bacterial infections in infancy and a maturation arrest at the promyelocyte stage. - **Common variable immunodeficiency (CVID)**: Characterized by hypogammaglobulinemia and recurrent infections, but without warts or myelokathexis. - **Myelokathexis alone**: Can occur as an isolated finding without the full WHIM phenotype, particularly in carriers of hypomorphic *CXCR4* mutations. Diagnosis of WHIM syndrome is confirmed by genetic testing for *CXCR4* mutations. Flow cytometric analysis of CXCR4 surface expression on neutrophils often shows increased receptor density, and functional assays demonstrate impaired receptor internalization in response to CXCL12. ## 5. Host-Pathogen & Viral Interactions ### 5.1 HIV-1 Entry Mechanism CXCR4 serves as a co-receptor for T-tropic (X4) and dual-tropic (R5X4) strains of HIV-1. The viral entry process is a multi-step cascade: 1. **CD4 binding**: The HIV-1 envelope glycoprotein gp120 binds to the primary receptor CD4 on the host cell surface. This binding induces a conformational change in gp120, exposing the co-receptor binding site (the V3 loop and the bridging sheet). 2. **Co-receptor binding**: The CD4-bound gp120 interacts with the N-terminus and ECL2 of CXCR4. The V3 loop of gp120 is the primary determinant of co-receptor specificity; X4 strains have a positively charged V3 loop that favors binding to the negatively charged CXCR4 N-terminus (due to sulfotyrosines). 3. **Membrane fusion**: Co-receptor binding triggers a further conformational change in gp41, the transmembrane subunit of the envelope glycoprotein. The fusion peptide of gp41 inserts into the host cell membrane, and the trimer of gp41 hairpins (six-helix bundle) forms, bringing the viral and cellular membranes into close apposition and driving membrane fusion. 4. **Core entry**: The viral capsid is released into the cytoplasm, where it undergoes uncoating and reverse transcription. ### 5.2 Viral Modulation of CXCR4 Expression HIV-1 infection itself modulates CXCR4 expression: - **Downregulation by Nef**: The HIV-1 accessory protein Nef binds to the cytoplasmic tail of CXCR4 and promotes its internalization and degradation via the endosomal pathway. This downregulation reduces superinfection and may also impair immune cell function. - **Downregulation by Vpu**: The Vpu protein enhances the degradation of CXCR4 through the ubiquitin-proteasome pathway, although the effect is less pronounced than for CD4. - **Envelope-mediated downregulation**: During viral budding, the envelope glycoprotein (gp160) can form complexes with CXCR4 in the endoplasmic reticulum, retaining the receptor intracellularly. ### 5.3 Other Viral Interactions - **Human papillomavirus (HPV)**: In WHIM syndrome, the increased susceptibility to HPV infection and the development of extensive warts are attributed to impaired CXCR4 internalization, which disrupts the trafficking of Langerhans cells and T cells to the skin. HPV itself does not directly interact with CXCR4. - **Epstein-Barr virus (EBV)**: EBV latent membrane protein 1 (LMP1) upregulates CXCR4 expression in B cells, promoting cell migration and potentially contributing to EBV-associated lymphomagenesis. - **Human T-lymphotropic virus type 1 (HTLV-1)**: The HTLV-1 Tax protein transactivates the *CXCR4* promoter, leading to increased receptor expression on infected T cells. This may contribute to the development of adult T-cell leukemia/lymphoma (ATLL). ### 5.4 Bacterial Interactions - **Helicobacter pylori**: The CagA oncoprotein of *H. pylori* upregulates CXCR4 expression in gastric epithelial cells, promoting cell migration and contributing to gastric carcinogenesis. - **Mycobacterium tuberculosis**: Infection of macrophages with *M. tuberculosis* downregulates CXCR4 expression, which may impair the recruitment of immune cells to the site of infection. ## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors ### 6.1 FDA-Approved Agents **Plerixafor (AMD3100, Mozobil)**: Plerixafor is a bicyclam small-molecule antagonist of CXCR4 that is FDA-approved for hematopoietic stem cell mobilization for autologous transplantation in patients with multiple myeloma and non-Hodgkin lymphoma. It functions by competitively blocking CXCL12 binding to CXCR4, thereby disrupting the retention of hematopoietic stem cells in the bone marrow niche. Plerixafor is administered subcutaneously at a dose of 0.24 mg/kg, typically 6-11 hours before apheresis. Common adverse effects include injection site reactions, diarrhea, nausea, and fatigue. ### 6.2 Investigational Small-Molecule Antagonists | Compound | Class | Mechanism | Development Stage | Indication | |---|---|---|---|---| | AMD070 (Mavorixafor) | Small molecule (benzimidazole) | Oral CXCR4 antagonist | Phase III (WHIM syndrome); Phase II (cancer) | WHIM syndrome; HIV-1; cancer | | LY2510924 | Cyclic peptide | CXCR4 antagonist | Phase II | Advanced solid tumors | | BKT140 (4F-benzoyl-TN14003) | Peptide | CXCR4 antagonist | Phase I/II | Multiple myeloma; acute myeloid leukemia | | POL6326 (Balixafortide) | Cyclic peptide | CXCR4 antagonist | Phase III (breast cancer) | Metastatic breast cancer | | USL311 | Small molecule | CXCR4 antagonist | Phase I/II | Glioblastoma; solid tumors | | TG-0054 (Burixafor) | Small molecule | CXCR4 antagonist | Phase II | Stem cell mobilization | ### 6.3 Monoclonal Antibodies - **Ulocuplumab (BMS-936564/MDX-1338)**: A fully human anti-CXCR4 monoclonal antibody that blocks CXCL12 binding and induces receptor internalization. It has been evaluated in Phase I/II trials for relapsed/refractory multiple myeloma, acute myeloid leukemia, and diffuse large B-cell lymphoma. - **PF-06747143**: A humanized anti-CXCR4 antibody with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). It is in Phase I trials for hematologic malignancies. ### 6.4 Gene Therapy and RNA-Based Approaches - **CXCR4 knockout via CRISPR-Cas9**: Ex vivo gene editing of autologous CD4+ T cells to disrupt *CXCR4* has been proposed as a strategy for HIV-1 resistance. Preclinical studies show that CXCR4-knockout T cells are resistant to X4-tropic HIV-1 infection and retain normal proliferative capacity. - **Short hairpin RNA (shRNA)**: Lentiviral delivery of shRNA targeting *CXCR4* mRNA has been shown to reduce receptor expression and inhibit HIV-1 replication in vitro. - **Antisense oligonucleotides (ASOs)**: ASOs targeting the *CXCR4* transcript are in preclinical development for cancer therapy. ### 6.5 Pharmacogenomic Considerations - **[CYP3A4](/knowledge/bioinformatics/genes/medical-genetics/cyp3a4-gene-structure-function-pathway) interactions**: Plerixafor is not extensively metabolized by cytochrome P450 enzymes, but co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole) may increase plerixafor exposure. - **Renal impairment**: Plerixafor is primarily excreted renally; dose adjustment is required for patients with creatinine clearance < 50 mL/min. - **WHIM syndrome mutations**: Patients with C-terminal truncating mutations (e.g., R334X) may respond differently to CXCR4 antagonists. Mavorixafor has shown efficacy in WHIM patients by restoring neutrophil egress from the bone marrow, but the optimal dose may vary based on the specific mutation. ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions for CXCR4 research. | Database | Accession/ID | URL | |---|---|---| | NCBI Gene | 7852 | https://www.ncbi.nlm.nih.gov/gene/7852 | | Ensembl | ENSG00000121966 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000121966 | | UniProt | P61073 | https://www.uniprot.org/uniprotkb/P61073 | | RCSB PDB | 3ODU | https://www.rcsb.org/structure/3ODU | | OMIM | 162643 (gene); 193670 (WHIM syndrome) | https://www.omim.org/entry/162643 | | ClinVar | Gene: CXCR4 | https://www.ncbi.nlm.nih.gov/clinvar/?term=CXCR4%5Bgene%5D | | Gene Ontology (GO) | GO:0004930 (GPCR activity); GO:0019957 (C-C chemokine binding); GO:0038023 (signaling receptor activity) | https://www.ebi.ac.uk/QuickGO/ | | STRING | 9606.ENSP00000345733 | https://string-db.org/ | | BioGRID | 109276 | https://thebiogrid.org/109276 | | COSMIC | Gene: CXCR4 | https://cancer.sanger.ac.uk/cosmic | | PharmGKB | PA27164 | https://www.pharmgkb.org/gene/PA27164 | | GTEx | CXCR4 | https://gtexportal.org/home/gene/CXCR4 | | Human Protein Atlas | ENSG00000121966 | https://www.proteinatlas.org/ENSG00000121966-CXCR4 | ## Related Clinical & Scientific Guides * [DPP4 (CD26): MERS-CoV Receptor Attachment, Dipeptidyl Peptidase Activity, and Metabolic Tropism](/knowledge/bioinformatics/genes/virology-receptors/dpp4-gene-structure-function-pathway) * [ANPEP (CD13): Aminopeptidase N Structure and Coronavirus Receptor Attachment Mechanisms](/knowledge/bioinformatics/genes/virology-receptors/anpep-gene-structure-function-pathway) * [TMPRSS2 (Transmembrane Protease Serine 2): Spike Cleavage Activation and Host Cell Entry](/knowledge/bioinformatics/genes/virology-receptors/tmprss2-gene-structure-function-pathway) ## References 1. Wu B, Chien EYT, Mol CD, Fenalti G, Liu W, Katritch V, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. *Science*. 2010;330(6007):1066-1071. doi:10.1126/science.1194396. URL: https://www.science.org/doi/10.1126/science.1194396 2. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. *Nature*. 1996;382(6594):829-833. doi:10.1038/382829a0. URL: https://www.nature.com/articles/382829a0 3. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. *Nature*. 1996;382(6594):833-835. doi:10.1038/382833a0. URL: https://www.nature.com/articles/382833a0 4. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. *Science*.